SAB Biotherapeutics SABS Cash Flow Statement (2020-2026)

NASDAQ SABS
$3.72 +0.00 (+0.00%)
As of: Sep 4, 2026 · 2:18 PM EDT
Reported Financials

SAB Biotherapeutics Quarterly Cash Flow Statement

Periods 23 quarters
Latest Jun 2026

SAB Biotherapeutics reported cash from operations of -$9.84M and free cash flow of -$11.43M for the quarter ended Jun 2026, down 37.6% year over year. This cash flow statement covers 23 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-4.06M-11.55M0.99M-4.78M-7.08M-7.85M-7.35M-6.88M-5.10M-22.86M-5.03M-7.34M-10.35M-9.94M-10.78M-9.78M-12.07M-15.13M-19.01M-21.73M
Share-based Compensation
0.88M0.65M5.56M5.29M7.45M0.63M9.60M9.94M9.82M1.99M2.07M1.89M3.10M0.67M2.96M2.94M11.80M2.79M38.96M92.80M
Gains from Investment Securities
-0.00M5.65M-7.85M-1.73M-0.78M-0.04M-0.08M0.36M-0.18M4.73M-5.47M-2.22M-0.01M2.31M-5.04M0.63M-61.60M3.25M0.48M1.11M
Change in Interest Receivables
0.19M0.03M-0.13M-0.04M-0.03M-0.02M0.56M0.39M0.61M0.29M
Cash from Operations
3.80M-4.88M-9.54M-4.45M-7.92M-1.56M-1.61M-4.90M-5.17M-13.45M-10.75M-7.72M-6.29M-9.53M-7.80M-7.15M-13.05M-16.78M-14.27M-9.84M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.04M0.04M0.04M0.03M0.02M0.02M0.03M0.02M0.02M0.03M0.08M0.02M0.02M0.02M0.02M0.02M0.02M0.03M0.02M0.02M
Amortization of Deferred Charges
0.04M0.04M0.04M0.03M0.02M
Depreciation & Amortization (CF)Depreciation & Amortization
0.37M0.62M0.64M0.75M0.89M0.93M0.90M0.90M1.00M0.97M2.00M1.00M0.90M0.76M0.80M0.80M0.70M0.70M0.73M0.80M
Change in Working Capital
Change in Receivables
-6.90M-2.20M3.78M-2.17M3.33M-7.39M-4.79M-0.40M-0.36M
Change in Account Payables
-1.40M0.34M0.52M-0.04M0.54M-1.81M-2.23M-0.04M-0.32M-0.11M0.24M-0.05M0.13M0.59M0.68M0.14M0.34M0.32M0.11M0.67M
Change in Accured Expenses
1.58M0.28M-0.60M-2.00M0.38M-0.32M-1.73M-0.76M-0.63M1.40M-1.58M-0.07M1.86M-1.44M0.58M1.04M-0.29M-0.39M-1.19M1.83M
Change in Taxes
0.09M
Other Working Capital Changes
-0.10M2.94M-0.04M-1.27M-0.31M-0.94M-0.26M-0.11M0.29M0.26M-2.13M6.86M0.30M-1.19M
Investing Activities
Capital Expenditures
3.23M2.36M1.36M0.61M0.08M0.12M0.02M0.02M0.09M0.07M0.13M0.05M0.10M0.06M0.98M1.59M
Sales of Property, Plant and Equipment
0.08M0.04M500.00500.00-500.000.00M783.00
Change in Acquisitions & Divestments
3.75M10.69M4.74M5.25M364.0011.27M74.60M9.71M
Cash from Investing Activities
-3.23M-2.36M-1.28M-0.61M-0.08M-0.12M-0.02M-0.02M-0.04M-0.07M-31.36M11.22M-1.15M9.33M4.67M5.20M-129.87M-1.71M-65.65M-4.88M
Financing Activities
Other financing activities
-4.17M0.01M0.07M1.00-1.000.00M0.00M59.65M0.02M-3.002.98M0.54M
Debt Issuance and Repayment
Long-Term Debt Issuances
2.69M0.76M0.76M0.25M3.75M0.33M0.33M0.11M0.26M0.22M0.22M0.62M0.24M0.14M0.14M3.00
Change in Capital Stock
Net Shares Issued and Repurchased
1.35M0.49M2.93M2.55M0.38M1.08M2.43M0.01M18.19M18.64M
Net Equity Issued and Repurchased
Misc.
Cash from Financing Activities
-0.05M36.03M-6.32M-0.73M-0.29M8.39M-0.36M-0.36M-0.14M67.64M-0.39M-0.32M-0.67M0.22M-0.17M-0.17M168.69M-0.04M89.92M2.36M
Exchange Rate Effect
-0.03M0.03M0.05M-0.29M0.04M0.18M-0.04M-0.40M0.01M0.11M
Change in Cash
0.52M28.79M-17.14M-5.79M-8.28M6.71M-1.99M-5.29M-5.35M54.14M-42.53M3.21M-8.07M-0.27M-3.26M-1.95M25.73M-18.92M10.02M-12.25M
Free Cash Flow
0.57M-7.24M-10.90M-5.06M-8.00M-1.67M-1.63M-4.92M-5.25M-13.51M-10.88M-7.77M-6.39M-9.59M-7.80M-7.15M-13.05M-16.78M-15.25M-11.43M
Net Cash Flow
0.52M28.79M-17.14M-5.79M-8.28M6.71M-1.99M-5.29M-5.35M54.12M-42.50M3.18M-8.12M0.02M-3.30M-2.13M25.77M-18.52M10.00M-12.36M